Sign inJoin waitlistJoin the waitlist

Andrew Sochacki

Physician · Cancer and Hematology Centers of Western Mi, P.c.

Credentials: · · · · · ·

History

Cancer and Hematology Centers of Western Mi, P.c.
2020–Present

Hematology and Medical Oncology
Vanderbilt University Medical Center
2017–2020
Internal Medicine
Vanderbilt University Medical Center
2014–2017
Michigan State University College of Human Medicine
2010–2014

Research

Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock
The Journal of Experimental Medicine · 2009 · 197 citations
Remodeling of retinal Fatty acids in an animal model of diabetes: a decrease in long-chain polyunsaturated fatty acids is associated with a decrease in fatty acid elongases Elovl2…
Diabetes · 2010 · 115 citations
The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models
Diabetes · 2011 · 88 citations

Michael Savona
6 papers
Alexander Bick
4 papers
Alexander Silver
4 papers · 4 as a resident
Ashwin Kishtagari
4 papers
Madalina Opreanu
4 papers · 1 as a resident
TS
Travis Spaulding
4 papers · 4 as a fellow
KB
Kelly Von Beck
3 papers · 2 as a resident
Maria Grant
3 papers
Aziz Nazha
2 papers · 1 as a fellow
Christina Snider
2 papers · 2 as a fellow
Jonathan Heimlich
2 papers · 2 as a fellow
Naval Daver
2 papers

Clinical trials

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Ottimo Pharma Limited
2025–2028
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Site PI · Recruiting · Phase 1, Phase 2
STORM Therapeutics LTD
2025–2028
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Site PI · Recruiting · Phase 1
SystImmune Inc.
2024–2027
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Site PI · Recruiting · Phase 1, Phase 2
GlaxoSmithKline
2023–2028